by Victoria Radke | Mar 29, 2021
The U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma. Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy given...
by Victoria Radke | Mar 1, 2021
The U.S. Food and Drug Administration (FDA) has approved Nulibry (fosdenopterin) to treat children with molybdenum cofactor deficiency type A. Molybdenum cofactor deficiency type A is a rare and often fatal metabolic disorder. It often presents in the first few days...
by Victoria Radke | Feb 25, 2021
The U.S. Food and Drug Administration (FDA) has approved a third exon-skipping medication to treat boys with Duchenne muscular dystrophy (DMD). More specifically, the FDA approved Amondys 45 (casimersen) to treat DMD patients who have a confirmed mutation of the DMD...
by Victoria Radke | Feb 17, 2021
The U.S. Food and Drug Administration (FDA) has approved the Patient Specific Talus Spacer 3D-printed talus implant for the treatment of avascular necrosis (AVN) of the ankle joint. AVN of the ankle joint is a serious and progressive condition that causes the death of...
by Victoria Radke | Jan 25, 2021
The U.S. Food and Drug Administration (FDA) has accepted Albireo Pharmaceuticals’ New Drug Application (NDA) for odevixibat for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The FDA is scheduled to make a decision on...
